JAZZ vs STRO · P/E 1988, rev $4.07B vs rev $62.0M
Jazz Pharmaceuticals PLC (JAZZ) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. STRO currently screens at market cap $470.8M.
Not investment advice. Open the JAZZ and STRO stock pages for the full models.
Not investment advice.